Article citationsMore>>

Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegård, G., Bokemeyer, C., Gascón, P., et al. (2004) The European Cancer Anaemia Survey (ECAS): A Large, Multinational, Prospective Survey Defining the Prevalence, Incidence, and Treatment of Anaemia in Cancer Patients. European Journal of Cancer, 40, 2293-2306.
https://doi.org/10.1016/j.ejca.2004.06.019

has been cited by the following article:

• TITLE: Alectinib-Induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma: Case Report and Literature Review

  AUTHORS: Chai Young Lee, Yon Ju Ryu

  KEYWORDS: Non-Small Cell Lung Cancer, Alectinib, Brigatinib, Hemolytic Anemia, Drug-Induced Hemolytic Anemia

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.13 No.8, August 28, 2024

  ABSTRACT: Alectinib is a selective Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitor used as standard therapy for ALK-rearranged lung adenocarcinoma. Hemolytic anemia is considered a rare but significant adverse event of alectinib. Here, we report the case of a 78-year-old female with advanced ALK rearrangement-positive lung adenocarcinoma who developed grade 4 drug-induced hemolytic anemia after receiving alectinib as first-line therapy. We discontinued alectinib treatment and switched to brigatinib. As a result, anemia improved without recurrence of lung adenocarcinoma over one year.